Market News & Trends
Foamix Announces Positive Results From Phase 3 Open-Label Safety Study Evaluating Topical Minocycline Foam
Foamix Pharmaceuticals Ltd. recently announced positive safety and efficacy data for its Phase 3 open-label safety study (FX2016-13), evaluating FMX103 in moderate-to-severe papulopustular rosacea for…
ABclonal Technology Partners With BenchSci to Boost Discoverability of its Novel Products
ABclonal Technology and BenchSci have recently entered into a partnership to provide scientists with high-class research tools for accelerating biomedical discoveries. Research scientists have always…
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study
Cellectar Biosciences, Inc. recently announced additional positive top-line results from its ongoing Phase 2 clinical study of CLR 131, the company’s lead product candidate. In…
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle…
BrainStorm Announces First Contracted US Clinical Site for Phase 2 Progressive MS Study
BrainStorm Cell Therapeutics Inc. recently announced Cleveland Clinic as the first US clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated…
Mogrify Raises $3.7 Million to Accelerate Mission to Transform Cell Therapy Via Direct Cellular Conversion
Cell Mogrify Ltd (Mogrify) recently announced a second close on its seed funding, bringing the total raised to $3.7 million, and the appointment of Darrin…
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial
ARCA biopharma, Inc. recently announced it has reached agreement with the US FDA regarding a Special Protocol Assessment (SPA) on the design of a pivotal…
Saama Partners With The Leukemia & Lymphoma Society & Unveils New Capabilities for Award-Winning Life Science Analytics Cloud
Saama Technologies, Inc. recently announced a new partnership with The Leukemia & Lymphoma Society (LLS), the world’s largest nonprofit dedicated to fighting blood cancers, to…
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of…
CytoDyn Files for Orphan Drug Designation for Triple-Negative Breast Cancer
CytoDyn Inc. recently announced it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model…